New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
August 12, 2024 - Ascendis Pharma announced the FDA approval of Yorvipath (palopegteriparatide), for the treatment of hypoparathyroidism in adults.
Download PDF
Return to publications
